{"id":3303,"date":"2025-03-19T18:58:03","date_gmt":"2025-03-19T15:58:03","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3303"},"modified":"2025-03-19T18:58:05","modified_gmt":"2025-03-19T15:58:05","slug":"satellos-presents-initial-data-from-the-phase-1-trial-of-sat-3247-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-presents-initial-data-from-the-phase-1-trial-of-sat-3247-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference\/","title":{"rendered":"Satellos, 2025 Musk\u00fcler Distrofi Derne\u011fi Klinik ve Bilimsel Konferans\u0131nda SAT-3247&#039;nin 1. Faz Denemesinden \u0130lk Verileri Sunuyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Kas hastal\u0131klar\u0131 ve bozukluklar\u0131n\u0131n tedavisini iyile\u015ftirmek i\u00e7in yeni k\u00fc\u00e7\u00fck molek\u00fcl terap\u00f6tik yakla\u015f\u0131mlar\u0131 geli\u015ftiren bir biyoteknoloji \u015firketi olan Satellos Bioscience, bug\u00fcn Dallas, Teksas&#039;ta d\u00fczenlenen 2025 Musk\u00fcler Distrofi Derne\u011fi (MDA) Klinik ve Bilimsel Konferans\u0131&#039;nda yapt\u0131\u011f\u0131 s\u00f6zl\u00fc sunumda ilk Faz 1 verilerini duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247, hasara yan\u0131t olarak rejenerasyonu geri kazand\u0131rmay\u0131 ama\u00e7layarak DMD hastalar\u0131ndaki ilerleyici kas kayb\u0131n\u0131 ele almak \u00fczere tasarlanm\u0131\u015ft\u0131r. SAT-3247 ile bir Faz 1 denemesi sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerde ve DMD&#039;li yeti\u015fkinlerde y\u00fcr\u00fct\u00fclmektedir (s\u0131ras\u0131yla Faz 1a ve Faz 1b).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-announces-completed-enrollment-of-phase-1-clinical-trial-of-sat-3247-in-healthy-volunteers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Satellos, Sa\u011fl\u0131kl\u0131 G\u00f6n\u00fcll\u00fclerde SAT-3247&#039;nin 1. Faz Klinik Denemesinin Tamamlanan Kayd\u0131n\u0131 Duyurdu<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247&#039;nin g\u00fcvenli\u011fini ve tolere edilebilirli\u011fini de\u011ferlendirmek \u00fczere tasarlanan Faz 1a&#039;da, 72 sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fc, 400 mg&#039;a kadar tek oral dozlar i\u00e7eren be\u015f tek artan doz (SAD) kohortu (bir g\u0131da etkisi kohortu dahil) ve 7 g\u00fcn boyunca g\u00fcnde 240 mg\/g\u00fcn&#039;e kadar g\u00fcnl\u00fck oral dozlar i\u00e7eren d\u00f6rt MAD kohortu aras\u0131nda randomize edildi. 20 \u015eubat 2025 itibar\u0131yla veri kesintisi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Faz 1a verileri, SAT-3247&#039;nin t\u00fcm sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fc kohortlar\u0131nda g\u00fcvenli ve iyi tolere edildi\u011fini g\u00f6sterdi. Tahmin edilen insan etkili doz seviyelerinde, SAT-3247 klinik laboratuvarlar, hayati bulgular, EKG ve fiziksel muayene dahil olmak \u00fczere \u00f6l\u00e7\u00fclen hi\u00e7bir parametrede olumsuz klinik bulgular g\u00f6stermedi. \u0130ncelenen herhangi bir dozda orta veya daha y\u00fcksek ila\u00e7la ili\u015fkili olumsuz olay bildirilmedi.<\/li>\n\n\n\n<li>Faz 1a PK verileri, \u015eirketin klinik \u00f6ncesi \u00e7al\u0131\u015fmalar\u0131ndan elde edilen sonu\u00e7larla tutarl\u0131l\u0131k g\u00f6sterdi. Bu PK sonu\u00e7lar\u0131, SAT-3247&#039;nin doz sonras\u0131 plazma konsantrasyonlar\u0131n\u0131n, bulgular\u0131n kas rejenerasyonu ve g\u00fcc\u00fc \u00fczerinde terap\u00f6tik bir etki yaratma olas\u0131l\u0131\u011f\u0131n\u0131n en y\u00fcksek oldu\u011funu g\u00f6sterdi\u011fi seviyelerde ve zaman dilimlerinde s\u00fcrd\u00fcr\u00fcld\u00fc\u011f\u00fcn\u00fc do\u011frulamaktad\u0131r.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos&#039;nin 2025&#039;in 2. \u00e7eyre\u011finde Faz 1a ve Faz 1b&#039;ye ili\u015fkin t\u00fcm verileri bildirmesi bekleniyor.<\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced initial Phase 1 data in an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference in Dallas, Texas. SAT-3247 is designed to address progressive muscle loss in DMD patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3304,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[297,251,252,253],"class_list":["post-3303","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-muscular-dystrophy-association","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3303"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3303\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3304"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}